Metabotropic glutamate receptor 5: a target for migraine therapy

Annals of Clinical and Translational Neurology

Volumn 3, Issue 8, 2016, Pages 560-571

  Waung, Maggie W ^a   Akerman, Simon ^a,d   Wakefield, Mark ^b,e   Keywood, Charlotte ^b,f   Goadsby, Peter J ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ADDEX PHARMACEUTICALS   (Switzerland)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f Minerva Pharmaceutical Consulting   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADX 10059; DIZOCILPINE; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; NARATRIPTAN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLURRED VISION; BRAIN DEPTH STIMULATION; CONTROLLED STUDY; CRANIOTOMY; DIPLOPIA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LAMINECTOMY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHONOPHOBIA; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; VERTIGO; VISUAL HALLUCINATION; VOMITING;

EID: 85014566236     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.302     Document Type: Article

References (44)

1. Global Burden of Disease Study. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;386:743–800.
2. Goadsby PJ, Lipton RB, Ferrari MD. Migraine–current understanding and treatment. N Engl J Med 2002;346:257–270.
3. Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003;290:2443–2454.
4. 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668–1675.
5. Goadsby PJ, Sprenger T. Current practice and future directions in the management of migraine: acute and preventive. Lancet Neurol 2010;9:285–298.
6. Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007;27:814–823.
7. Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 2010;6:573–582.
8. Goadsby PJ. Incredible progress in migraine for an era of better care. Nat Rev Neurol 2015;11:621–622.
9. Hoskin KL, Kaube H, Goadsby PJ. Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. Brain 1996;119:1419–1428.
10. Hoskin KL, Zagami A, Goadsby PJ. Stimulation of the middle meningeal artery leads to Fos expression in the trigeminocervical nucleus: a comparative study of monkey and cat. J Anat 1999;194:579–588.
11. Bergerot A, Holland PR, Akerman S, et al. Animal models of migraine. Looking at the component parts of a complex disorder. Eur J Neurosci 2006;24:1517–1534.
12. Gasparini F, Kuhn R, Pin JP. Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectives. Curr Opin Pharmacol 2002;2:43–49.
13. Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997;37:205–237.
14. Mao L, Yang L, Tang Q, et al. The scaffold protein Homer1b/c links metabotropic glutamate receptor 5 to extracellular signal-regulated protein kinase cascades in neurons. J Neurosci 2005;25:2741–2752.
15. Storer RJ, Goadsby PJ. Trigeminovascular nociceptive transmission involves N-methyl-D-aspartate and non-N-methyl-D-aspartate glutamate receptors. Neuroscience 1999;90:1371–1376.
16. Knight YE, Goadsby PJ. The periaqueductal gray matter modulates trigeminovascular input: a role in migraine? Neuroscience 2001;106:793–800.
17. Mitsikostas DD, Sanchez del Rio M, Waeber C, et al. Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis. Br J Pharmacol 1999;127:623–630.
18. Gomez-Mancilla B, Brand R, Jurgens TP, et al. Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks. Cephalalgia 2014;34:103–113.
19. Sang CN, Ramadan NM, Wallihan RG, et al. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 2004;24:596–602.
20. Johnson KW, Nisenbaum ES, Johnson MP, et al. Innovative drug development for headache disorders: glutamate. In: Olesen J, Ramadan N, eds. Innovative drug development for headache disorders. Oxford: Oxford University Press, 2008. p. 185–194.
21. Shigemoto R, Nakanishi S, Mizuno N. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR1) in the central nervous system: an in situ hybridization study in adult and developing rat. J Comp Neurol 1992;322:121–135.
22. Shigemoto R, Nomura S, Ohishi H, et al. Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci Lett 1993;163:53–57.
23. Zerbib F, Bruley des Varannes S, Roman S, et al. Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2011;33:911–921.
24. Marin JCA, Goadsby PJ. Glutamatergic fine tuning with ADX-10059- a novel therapeutic approach for migraine? Expert Opin Emerg Drugs 2010;19:555–561.
25. Akerman S, Holland PR, Lasalandra M, Goadsby PJ. Endocannabinoids in the brainstem modulate dural trigeminovascular nociceptive traffic via CB1 and ‘triptan’ receptors: implications in migraine. J Neurosci 2013;33:14869–14877.
26. Holland PR, Akerman S, Andreou AP, et al. Acid-sensing ion channel-1: a novel therapeutic target for migraine with aura. Ann Neurol 2012;72:559–563.
27. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders (second edition). Cephalalgia 2004;24(Suppl 1):1–160.
28. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. European Medicines Agency, ed. Statistical principles for clinical trials. Geneva: International Conference on Harmonisation, 1998.
29. Walker K, Bowes M, Panesar M, et al. Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function. I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain. Neuropharmacology 2001;40:1–9.
30. Kawasaki Y, Kohno T, Zhuang ZY, et al. Ionotropic and metabotropic receptors, protein kinase A, protein kinase C, and Src contribute to C-fiber-induced ERK activation and cAMP response element-binding protein phosphorylation in dorsal horn neurons, leading to central sensitization. J Neurosci 2004;24:8310–8321.
31. Li B, Lu L, Tan X, et al. Peripheral metabotropic glutamate receptor subtype 5 contributes to inflammation-induced hypersensitivity of the rat temporomandibular joint. J Mol Neurosci 2013;51:710–718.
32. Bhave G, Karim F, Carlton SM, Gereau RW IV. Peripheral group I metabotropic glutamate receptors modulate nociception in mice. Nat Neurosci 2001;4:417–423.
33. Farkkila M, Diener HC, Geraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 2012;11:405–413.
34. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008;372:2115–2123.
35. May A, Goadsby PJ. Substance P receptor antagonists in the therapy of migraine. Expert Opin Investig Drugs 2001;10:1–6.
36. Palmer JE, Guillard FL, Laurijssens BE, et al. A randomised, single-blind, placebo-controlled, adaptive clinical trial of GW274150, a selective iNOS inhibitor, in the treatment of acute migraine. Cephalalgia 2009;29:124.
37. Dodick DW, Goadsby PJ, Silberstein SD, et al. Randomized, double-blind, placebo-controlled, phase II trial of ALD403, an anti-CGRP peptide antibody in the prevention of frequent episodic migraine. Lancet Neurol 2014;13:1100–1107.
38. Dodick DW, Goadsby PJ, Spierings ELH, et al. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study. Lancet Neurol 2014;13:885–892.
39. Bigal ME, Dodick DW, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 2015;14:1081–1090.
40. Bigal ME, Edvinsson L, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 2015;14:1091–1100.
41. Sun H, Dodick DW, Silberstein S, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2016;15:382–390.
42. Rascol O, Fox S, Gasparini F, et al. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. Parkinsonism Relat Disord 2014;20:947–956.
43. Simmons RM, Li DL, Hoo KH, et al. Kainate GluR5 receptor subtype mediates the nociceptive response to formalin in the rat. Neuropharmacology 1998;37:25–36.
44. Sang CN, Hostetter MP, Gracely RH, et al. AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans. Anesthesiology 1998;89:1060–1067.